NuCana (NCNA) Receivables (2016 - 2025)
NuCana (NCNA) reported Receivables of $1.1 million for Q4 2025, down 6.4% on a YoY basis from $1.2 million in Q4 2024, and down 71.88% sequentially from $4.0 million in Q3 2025.
NuCana (NCNA) Receivables (2016 - 2025) Analysis & Trends
NuCana (NCNA) has 10 years of Receivables data on file, last reported at $1.1 million in Q4 2025.
- For the quarter ending Q4 2025, Receivables fell 6.4% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $1.1 million (down 6.4% YoY), and the FY2025 full-year result was $1.1 million, down 6.84% from the prior year.
- Receivables declined to $1.1 million in Q4 2025, from $4.0 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $8.3 million in Q3 2022 to a low of $1.1 million in Q4 2025.
- A 5-year average of $4.1 million and a median of $4.2 million in 2023 frame the typical range for Receivables.
- Across the five-year window, Receivables slumped 65.72% in 2024 and soared 170.87% in 2025, its largest moves.
- Tracing NCNA's Receivables over 5 years: stood at $5.6 million in 2021, then decreased by 17.14% to $4.7 million in 2022, then fell by 28.35% to $3.3 million in 2023, then slumped by 63.85% to $1.2 million in 2024, then slipped by 6.4% to $1.1 million in 2025.
- Business Quant data shows NCNA's Receivables at $1.1 million in Q4 2025, $4.0 million in Q3 2025, and $1.4 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 883.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 4.02 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.54 Mn |
| Dec 31, 2024 | 1.21 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 2.58 Mn |
| Mar 31, 2024 | 3.51 Mn |
| Dec 31, 2023 | 3.34 Mn |
| Sep 30, 2023 | 4.32 Mn |
| Jun 30, 2023 | 3.27 Mn |
| Mar 31, 2023 | 5.31 Mn |
| Dec 31, 2022 | 4.66 Mn |
| Sep 30, 2022 | 8.31 Mn |
| Jun 30, 2022 | 4.95 Mn |
| Mar 31, 2022 | 5.09 Mn |
| Dec 31, 2021 | 5.62 Mn |
| Sep 30, 2021 | 7.08 Mn |
| Jun 30, 2021 | 5.87 Mn |
| Mar 31, 2021 | 6.64 Mn |